Apimeds Pharmaceuticals appoints Dr. Christopher Kim as chief scientific officer

Apimeds Pharmaceuticals US, Inc. (NYSE American:APUS) announced Wednesday the appointment of Dr. Christopher Kim as its Chief Scientific Officer, effective immediately. The company disclosed the leadership change in a statement included in a Securities and Exchange Commission filing.

According to the filing, Dr. Kim will oversee the scientific, clinical, and regulatory development of the company’s APITOX program. His responsibilities will include leading research and development, shaping clinical strategy, managing regulatory engagement, and advancing activities directed toward obtaining regulatory approvals and commercialization of the APITOX program.

The company noted that Dr. Kim has been closely associated with the APITOX program for several years and brings significant scientific, technical, and regulatory expertise to the role. Apimeds Pharmaceuticals stated that his appointment is intended to provide continuity in the program’s leadership as it advances through the regulatory process.

Apimeds Pharmaceuticals is incorporated in Delaware and is headquartered in Matawan, New Jersey. The company is classified under pharmaceutical preparations and is listed on the NYSE American exchange under the ticker symbol APUS.

This information is based on a press release statement included in the company’s recent SEC filing.